Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Pietro Lampertico*, Stefan Mauss, Marcello Persico, Stephen T. Barclay, Steven Marx, Kristina Lohmann, Mark Bondin, Zhen Zhen Zhang, Fiona Marra, Pamela S. Belperio, Heiner Wedemeyer, Steven Flamm

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Introduction: More than 70 million people are estimated to be infected with hepatitis C virus globally. Glecaprevir/pibrentasvir is a widely used treatment and has recently been approved for an 8-week regimen for treatment-naïve patients with compensated cirrhosis in Europe and the USA, who would previously have received glecaprevir/pibrentasvir for 12 weeks. This label update was based on the EXPEDITION-8 study, which included 343 treatment-naïve patients with compensated cirrhosis. However, there is currently a lack of similarly large-scale real-world studies of the 8-week glecaprevir/pibrentasvir regimen in this population. Methods: This summary of seven separate smaller real-world studies aims to validate the results seen in EXPEDITION-8 and provide an up-to-date real-world reference for clinicians making treatment decisions for patients with compensated cirrhosis (Child–Pugh A) who may benefit from a shorter-duration therapy with glecaprevir/pibrentasvir. The newly emerging real-world effectiveness data on treatment-naïve patients with compensated cirrhosis treated with 8 weeks of glecaprevir/pibrentasvir help to understand where further research is needed to support patients with hepatitis C virus. Results: Across all seven studies, glecaprevir/pibrentasvir showed high effectiveness with an average sustained virologic response rate of 98.1%, similar to that found in a clinical trial setting (99.7%). Only one patient (0.5%) experienced virologic failure and treatment was well tolerated. Conclusion: Expanding the number of patients eligible for the shortened treatment duration will potentially increase treatment initiation and completion, particularly in underserved populations, contributing to the elimination of hepatitis C virus.

Original languageEnglish (US)
Pages (from-to)4033-4042
Number of pages10
JournalAdvances in Therapy
Issue number9
StatePublished - Sep 1 2020


  • Fibrosis
  • Hepatitis C
  • Infectious disease
  • Review
  • Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis'. Together they form a unique fingerprint.

Cite this